Last reviewed · How we verify
Indometacin Cataplasms
Indometacin Cataplasms is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. It is currently FDA-approved for Topical treatment of localized inflammation and pain (e.g., joint pain, muscle pain, arthritis), Traditional Chinese medicine application for inflammatory conditions.
Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain when applied topically as a cataplasm (poultice).
Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain when applied topically as a cataplasm (poultice). Used for Topical treatment of localized inflammation and pain (e.g., joint pain, muscle pain, arthritis), Traditional Chinese medicine application for inflammatory conditions.
At a glance
| Generic name | Indometacin Cataplasms |
|---|---|
| Sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management / Inflammation |
| Phase | FDA-approved |
Mechanism of action
Indomethacin blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. When formulated as a cataplasm (medicated paste or poultice applied to skin), it delivers the drug locally to affected tissues, reducing inflammatory mediators at the site of application. This topical delivery minimizes systemic exposure compared to oral formulations.
Approved indications
- Topical treatment of localized inflammation and pain (e.g., joint pain, muscle pain, arthritis)
- Traditional Chinese medicine application for inflammatory conditions
Common side effects
- Local skin irritation or rash
- Contact dermatitis
- Mild burning or stinging at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Indometacin Cataplasms CI brief — competitive landscape report
- Indometacin Cataplasms updates RSS · CI watch RSS
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences portfolio CI
Frequently asked questions about Indometacin Cataplasms
What is Indometacin Cataplasms?
How does Indometacin Cataplasms work?
What is Indometacin Cataplasms used for?
Who makes Indometacin Cataplasms?
What drug class is Indometacin Cataplasms in?
What development phase is Indometacin Cataplasms in?
What are the side effects of Indometacin Cataplasms?
What does Indometacin Cataplasms target?
Related
- Drug class: All Nonsteroidal anti-inflammatory drug (NSAID) drugs
- Target: All drugs targeting Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
- Manufacturer: Guang'anmen Hospital of China Academy of Chinese Medical Sciences — full pipeline
- Therapeutic area: All drugs in Rheumatology / Pain Management / Inflammation
- Indication: Drugs for Topical treatment of localized inflammation and pain (e.g., joint pain, muscle pain, arthritis)
- Indication: Drugs for Traditional Chinese medicine application for inflammatory conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing